Page 43 - Read Online

Moriguchi et al. Hepatoma Res 2019;5:43 I http://dx.doi.org/10.20517/2394-5079.2019.20 Page 11 of 14

31. European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer. EASL-EORTC
clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012;56:908-43.
32. Weinmann A, Alt Y, Koch S, Nelles C, Düber C, et al. Treatment and survival of non-alcoholic steatohepatitis associated
hepatocellular carcinoma. BMC Cancer 2015;15:210.
33. Reddy SK, Steel JL, Chen HW, DeMateo DJ, Cardinal J, et al. Outcomes of curative treatment for hepatocellular cancer in
nonalcoholic steatohepatitis versus hepatitis C and alcoholic liver disease. Hepatology 2012;55:1809-19.
34. Wakai T, Shirai Y, Sakata J, Korita PV, Ajioka Y, et al. Surgical outcomes for hepatocellular carcinoma in nonalcoholic fatty liver
disease. J Gastrointest Surg 2011;15:1450-8.
35. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied
cohort of U.S. adults. N Engl J Med 2003;348:1625-38.
36. Guzman G, Brunt EM, Petrovic LM, Chejfec G, Layden TJ, et al. Does nonalcoholic fatty liver disease predispose patients to
hepatocellular carcinoma in the absence of cirrhosis? Arch Pathol Lab Med 2008;132:1761-6.
37. Cholankeril G, Patel R, Khurana S, Satapathy SK. Hepatocellular carcinoma in non-alcoholic steatohepatitis: current knowledge and
implications for management. World J Hepatol 2017;9:533-43.
38. Siegel AB, Zhu AX. Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link. Cancer
2009;115:5651-61.
39. Wong VW, Wong GL, Choi PC, Chan AW, Li MK, et al. Disease progression of non-alcoholic fatty liver disease: a prospective study
with paired liver biopsies at 3 years. Gut 2010;59:969-74.
40. Pais R, Charlotte F, Fedchuk L, Bedossa P, Lebray P, et al. A systematic review of follow-up biopsies reveals disease progression in
patients with non-alcoholic fatty liver. J Hepatol 2013;59:550-6.
41. McPherson S, Hardy T, Henderson E, Burt AD, Day CP, et al. Evidence of NAFLD progression from steatosis to fibrosing-
steatohepatitis using paired biopsies: implications for prognosis and clinical management. J Hepatol 2015;62:1148-55.
42. Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal WZ, et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and
obesity. Nature 2012;482:179-85.
43. Lee RG. Nonalcoholic steatohepatitis: a study of 49 patients. Hum Pathol 1989;20:594-608.
44. Schlesinger S, Aleksandrova K, Pischon T, Fedirko V, Jenab M, et al. Abdominal obesity, weight gain during adulthood and risk of
liver and biliary tract cancer in a European cohort. Int J Cancer 2013;132:645-57.
45. Larsson SC, Wolk A. Overweight, obesity and risk of liver cancer: a meta-analysis of cohort studies. Br J Cancer 2007;97:1005-8.
46. Turati F, Talamini R, Pelucchi C, Polesel J, Franceschi S, et al. Metabolic syndrome and hepatocellular carcinoma risk. Br J Cancer
2013;108:222-8.
47. Oh SW, Yoon YS, Shin SA. Effects of excess weight on cancer incidences depending on cancer sites and histologic findings among
men: Korea National Health Insurance Corporation Study. J Clin Oncol 2005;23:4742-54.
48. Hassan MM, Abdel-Wahab R, Kaseb A, Shalaby A, Phan AT, et al. Obesity early in adulthood increases risk but does not affect
outcomes of hepatocellular carcinoma. Gastroenterology 2015;149:119-29.
49. Adami HO, Chow WH, Nyrén O, Berne C, Linet MS, et al. Excess risk of primary liver cancer in patients with diabetes mellitus. J
Natl Cancer Inst 1996;88:1472-7.
50. Raff EJ, Kakati D, Bloomer JR, Shoreibah M, Rasheed K, et al. Diabetes mellitus predicts occurrence of cirrhosis and hepatocellular
cancer in alcoholic liver and non-alcoholic fatty liver diseases. J Clin Transl Hepatol 2015;3:9-16.
51. Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Diabetes increases the risk of hepatocellular carcinoma in the United
States: a population based case control study. Gut 2005;54:533-9.
52. Yang JD, Mohamed HA, Cvinar JL, Gores GJ, Roberts LR, et al. Diabetes mellitus heightens the risk of hepatocellular carcinoma
except in patients with hepatitis C cirrhosis. Am J Gastroenterol 2016;111:1573-80.
53. Kasmari AJ, Welch A, Liu G, Leslie D, McGarrity T, et al. Independent of cirrhosis, hepatocellular carcinoma risk is increased with
diabetes and metabolic syndrome. Am J Med 2017;130:746.e1-746.e7.
54. Koh WP, Wang R, Jin A, Yu MC, Yuan JM. Diabetes mellitus and risk of hepatocellular carcinoma: findings from the Singapore
Chinese Health Study. Br J Cancer 2013;108:1182-8.
55. El-Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of
epidemiologic evidence. Clin Gastroenterol Hepatol 2006;4:369-80.
56. Sanna C, Rosso C, Marietti M, Bugianesi E. Non-alcoholic fatty liver disease and extra-hepatic cancers. Int J Mol Sci 2016;17:pii:
E717.
57. Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, et al. Beyond insulin resistance in NASH: TNF-alpha or adiponectin?
Hepatology 2004;40:46-54.
58. Gilbert CA, Slingerland JM. Cytokines, obesity, and cancer: new insights on mechanisms linking obesity to cancer risk and
progression. Annu Rev Med 2013;64:45-57.
59. Singal AG, Yopp AC, Gupta S, Skinner CS, Halm EA, et al. Failure rates in the hepatocellular carcinoma surveillance process. Cancer
Prev Res (Phila) 2012;5:1124-30.
60. Yatsuji S, Hashimoto E, Tobari M, Taniai M, Tokushige K, et al. Clinical features and outcomes of cirrhosis due to non-alcoholic
steatohepatitis compared with cirrhosis caused by chronic hepatitis C. J Gastroenterol Hepatol 2009;24:248-54.
61. Bhaskaran K, Douglas I, Forbes H, dos-Santos-Silva I, Leon DA, et al. Body-mass index and risk of 22 specific cancers: a population-
based cohort study of 5·24 million UK adults. Lancet 2014;384:755-65.